Correlation of serum fatty acid binding protein-4 and interleukine-6 with airflow limitation and quality of life in stable and acute exacerbation of COPD

Abstract

Background/aim: The serum fatty acid binding protein 4 (FABP-4) level increases in chronic inflammatory diseases. The present study aimed to examine serum FABP-4 and interleukin (IL)-6 levels in patients with stable and acute exacerbation of chronic obstructive pulmonary disease (COPD) and the correlation of these markers with airflow limitation.

Materials and methods: We measured serum FABP-4 and IL-6 levels in 60 COPD patients [30 stable COPD (SCOPD), and 30 acute exacerbation of COPD (AECOPD)], and 30 healthy subjects and compared them with airflow limitation according to the COPD stage in the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) criteria, peripheral O\textsuperscript{2} saturation (SpO\textsubscript{2}), and COPD Assessment Test (CAT) score. We also tested the association between serum FABP-4 levels and some characteristics of study parameters.

Results: Both serum FABP-4 and IL-6 levels increased with increasing severity of GOLD grades in SCOPD (P < 0.01 for both) and AECOPD groups (P < 0.001 and P < 0.01, respectively). It also increased in patients with AECOPD group compared with SCOPD group in GOLD grades I-II (P < 0.01) and GOLD grades III-IV (P < 0.05). In addition, there was a significant positive correlation between serum FABP-4 level with IL-6, CAT score and smoking history and inversely with FEV\textsubscript{1} and SpO\textsubscript{2}.

Conclusion: The study revealed that serum FABP-4 level was elevated with increasing GOLD grades in COPD patients, markedly in acute exacerbation phase. The increase was
associated with elevated serum levels of IL-6 and severity of hypoxia. Thus, it seems that FABP-4 may be involved in the pathogenesis of COPD.

**Key words:** Chronic obstructive pulmonary disease, fatty acid binding protein 4, interleukin-6, airflow limitation.

1. **Introduction**

Chronic obstructive pulmonary disease (COPD) is one of the diseases that deeply affect morbidity and mortality in the world [1]. The limitation of air flow is the main characteristic of the disease, which is usually associated with airway inflammation [1]. On the other hand, acute exacerbation of COPD (AECOPD) is characterized by increased systemic inflammation, worsening of pulmonary function tests, increased sputum production, worsening of dyspnea and cough, and reduced health-associated quality of life, all of which affect the patient’s survival [2]. Similar to other diseases that are not characterized by specific etiology, various factors contribute to the pathogenesis of the disease, including abnormal immune responses, environmental and hormonal factors, and variable gene expression [3].

It has been well-known that under the conditions of AECOPD there is severe airway and systemic inflammation [4]. Additionally, systemic inflammatory markers and cytokines such as interleukin-6 (IL-6), IL-8, fibrinogen, α1-antitrypsin, myeloperoxidase, C-reactive protein (CRP), and tumor necrosis factor alpha (TNF-α) are high with COPD in the exacerbation phase [3, 4]. Despite extensive evidence, the precise mechanism of systemic inflammation in AECOPD is not completely clear. It has been reported that a variety of markers and cytokines peak during AECOPD.

Adipokines (also known as adipocytokines) are adipocyte-secreted protein mediators that not only regulate energy metabolism, but they also control inflammatory
responses in many chronic diseases [5-7]. Much evidence has shown that adipokines are involved in the lung inflammatory diseases, such as asthma and COPD [8, 9]. One of the recently suggested adipokines, fatty acid binding protein 4 (FABP-4) (also known as adipocyte-protein 2 or aP2), is produced by various cells such as adipocytes, endothelial cells, and macrophages [10]. It has been shown that FABP-4 has a regulatory role in lipid and glucose homeostasis, reactive oxygen species (ROS) production, the inflammatory processes, and secretion of leukotrienes [11, 12]. FABP-4 promotes the secretion of pro-inflammatory cytokines such as IL-6 and TNF-α, which exacerbates the severity of the disease in inflammatory disease [13]. On the other hand, it has been shown that by inhibiting the expression of FABP-4 by pharmacological and genetic studies, many inflammatory signals are inhibited, including the production of inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), and inflammatory cytokines such as IL-6, IL-1β, TNF-α [14]. In animal studies with an allergic airway inflammation model in FABP-4-knockout mice, reduced levels of cytokines and inflammatory cells in the lung tissue have been shown [15]. In addition, elevated serum levels of FABP-4 have been reported in chronic inflammatory diseases, such as asthma, rheumatoid arthritis, hypertension, insulin resistance, obesity, cardiac dysfunction, type 2 diabetes, atherosclerosis, acute lung injury, and female stable COPD [16]. The present study was conducted to evaluate serum FABP-4 and IL-6 levels in men with stable and acute exacerbation of COPD. Another aim of this study was to evaluate the relationship between serum FABP-4 levels and the severity of disease based on Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) grades and clinical assessment of disease severity based on COPD Assessment Test (CAT) in patients with COPD.

2. **Materials and methods**
2.1. Study Participants

In the current study, 90 subjects were divided into three groups including 30 patients with stable COPD (SCOPD), 30 patients with acute exacerbation of COPD (AECOPD), and 30 healthy subjects who were enrolled from April 2017 to March 2018. All subjects were male and matched for age. Patients with a diagnosis of SCOPD were recruited from a respiratory clinic and patients with AECOPD were selected from among those admitted to the emergency department of Ardabil Imam Khomeini Educational and Clinical Hospital, Ardabil, Iran. The control group consisted of subjects with normal spirometry with no respiratory symptoms who were selected from the same hospital who visited in other outpatient clinics.

The SCOPD and AECOPD were diagnosed according to the American Thoracic Society (ATS) guidelines [17]. The AECOPD refers to a sudden worsening of COPD symptoms in the form of shortness of breath, chronic worsening of the cough, and increased volume or discoloration of the phlegm. The inclusion criterion for COPD patients was a ratio of the forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) <70%. Exclusion criteria were history of hospitalization in the previous four weeks, cardiac ischemia, chronic inflammatory diseases, infectious disease, diabetes, metabolic syndrome, chronic renal failure, and cancer.

The pulmonary function testing was performed using a spirometer (Chest Inc., 801, Tokyo, Japan) according to ATS guidelines under standard conditions. Pulmonary function and biochemical tests were conducted on the same day for SCOPD and control subjects, but for the AECOPD patients they were carried out one day after admission to the hospital. The GOLD grades and COPD assessment test (CAT) questionnaire were fully completed for all patients described previously [18].
2.2. Biochemical measurements

Approximately 3-5 ml of blood samples was taken from all patients to determine serum levels of FABP-4 and IL-6. Serum FABP-4 and IL-6 concentrations were measured using a commercial kit (Crystal day, China) and an electrochemiluminescent method with an Elecsys 2010 Automated Analyzer (Roche Diagnostics). The results were reported as ng/mL.

2.3. Statistical Analysis

The results are presented as mean ± standard deviation (SD), or median and 25th–75th percentiles. Continuous variables were compared using the student’s t-test. Comparison between groups was made by ANOVA test was performed with Tukey Kemar post hoc test; alternatively, the Kruskal-Wallis test; if significant, it was followed by the Mann-Whitney U test for post hoc analysis. Correlation coefficients were assessed using the Pearson’s (or Spearman rank order) correlation test. Linear regression analyses were performed using FABP-4 as dependent variable and IL-6, FEV1, cigarette history (pack/year), GOLD grade, and Spo2 as independent variables. A value of \( P < 0.05 \) was considered significant. SPSS version 16.0 and Graph Pad Prism 5 software were used for statistical analysis.

3. Results

3.1. Baseline Characteristics of Study Population

The study population consisted of 90 men, comprising 30 control subjects, 30 patients with SCOPD, and 30 patients with AECOPD. In the control group the mean age was 58.13 ± 7.36 years and that of the COPD group was 58.70 ± 8.01 years (\( P = 0.730 \)) (Table 1).
The serum FABP-4 levels were significantly higher in the AECOPD group than in the control and SCOPD groups (P = 0.000 for both, Figure 1a). In addition, there was a significant difference in FABP-4 serum level between SCOPD and control subjects (P = 0.010, Figure 1a). Further, IL-6 results revealed higher levels of IL-6 in AECOPD group than in control and SCOPD groups (P = 0.000 for both, Figure 1b). On the other hand, serum levels of IL-6 in SCOPD group was higher than control subjects (P = 0.023, Figure 1b).

3.2. Severity of Chronic Obstructive Pulmonary Disease and Baseline Characteristics of the Study Population

Baseline parameters of the study population for COPD severity based on GOLD grade are presented in Table 2. There were statistically significant differences in SpO2 (P = 0.003), smoking history (pack/year) (P = 0.002), CAT score (P = 0.000), FABP-4 level (P = 0.000), and IL-6 (P = 0.000) between the COPD groups based on GOLD grade. We, however, found no significant differences in age (P = 0.849) and BMI (P = 0.735) according to the stages of COPD.

All grade III-IV patients have higher levels of FABP-4 and IL-6 that the lower grades both in AECOPD and stable patients (P < 0.01 to P <0.001, Table 2). The AECOPD patients had higher FABP-4 and IL-6 than stable patients in all COPD grades (P < 0.05 and P < 0.001, respectively) (Figure 2a and 2b).

The results showed that in both AECOPD and SCOPD groups, CAT scores were statistically higher in GOLD grades III-IV compared to stages I-II (P = 0.000 for both) (Table 2).

3.3. Relationship between Serum Levels of Fatty Acid Binding Protein-4 plus IL-6 and Parameters of Pulmonary Function
With regard to study parameters, serum FABP-4 levels were significantly associated with FEV1\% predicted (r = –0.716, P = 0.000; Figure 3a), FVC\% predicted (r = –0.670, P = 0.000), GOLD grades (r = 0.603, P = 0.000), and smoking history (pack/year) (r = 0.619, P = 0.000; Figure 3b). There were also significant correlations between serum FABP-4 levels and CAT score (r = 0.639, P = 0.000), and SpO2 (r = –0.537, P = 0.000; Figure 3c) (Table 3).

Further, the results showed that there were significant associations between IL-6 and FEV1\% predicted (r = –0.666, P = 0.000; Figure 3d), smoking history (pack/year) (r = 0.644, P = 0.000; Figure 3e), and SpO2 (r = –0.640, P = 0.000; Figure 3f). Interestingly, there were also significant correlations between serum levels of FABP-4 and IL-6 (r = 0.692, P = 0.000; Figure g).

Finally, a multiple regression was run to predict FABP-4 from IL-6, CAT score, and Spo2. These variables significantly predicted FABP-4, with F (4, 55) = 30.88, P < 0.001, R\(^2\) = 0.692. The results showed that the most significant predictors of FABP-4 were IL-6 and CAT score (P < 0.01 and P < 0.001, respectively) (Table 4).

4. Discussion

In this study, serum FABP-4 and IL-6 levels were significantly elevated with disease severity based on GOLD grades in patients with stable and acute exacerbation of COPD. Further, the serum FABP-4 and IL-6 levels were significantly higher in patients with stages III-IV COPD than in stages I-II according to GOLD grade. There was a negative correlation between serum FABP-4 levels and SpO2 as well as with FEV1. On the other hand, there was a positive correlation between serum FABP-4 levels and IL-6 as well as with severity of COPD based on GOLD grade.
The main symptom of COPD, especially its acute exacerbation phase, is the high level of inflammation that plays a key role in the development of disease [3]. It has been shown that in patients with SCOPD and AECOPD there is an over-production of various types of inflammatory cytokines, such as IL-6, TNF-α, and IL-1β, likely to stimulate downstream of cytokines to exacerbate pulmonary tissue damage [3, 19]. IL-6 is a pro-inflammatory cytokine produced predominantly by a variety of pulmonary cells, including airways epithelial cells, endothelial cells, alveolar macrophage, and fibroblast [20]. Our results indicated that serum IL-6 levels of AECOPD patients were higher than those in healthy subjects. In addition, it was found that the amount of IL-6 serum levels in AECOPD of patients was higher than that in SCOPD patients. Also, the results of IL-6 serum levels based on the severity of the disease revealed that in stages III-IV the amount of IL-6 was higher than stages I-II, which was in line with previous studies [20].

Many studies have shown that a variety of adipokines play an important role in chronic inflammatory diseases such as asthma and COPD [13, 21]. Indeed, adipokines are modulating mediators of inflammatory and immune responses [22]. FABP-4, as adipokine, is a cytosolic protein that is involved in the lipid trafficking and signaling [23]. Many evidence reported that elevated FABP-4 concentrations have been associated with insulin resistance, obesity, asthma, hypertension, cardiac dysfunction, type 2 diabetics, atherosclerosis, acute lung injury, and stable COPD [16]. It has been indicated that FABP-4 has a regulatory role in the allergic airway inflammation and that blocking FABP-4 causes a decline in airway inflammation in lung diseases [15]. However, there are few studies about the association of FABP-4 with COPD severity of disease, especially in acute exacerbation phase. Zhang et al. revealed that there was a gender difference in serum FABP-4 level in patients with stable COPD [13]. In their study, it was found that
in patients with stable COPD, the serum level of FABP-4 in females was higher than that in males and correlated negatively with pulmonary function tests and positively with TNF-α, CRP, and adiponectin levels [13]. In the current study, we found that the serum FABP-4 level in male patients with SCOPD was higher than control subjects. Although it is not clear to us whether the statistical difference between the levels of FABP-4 in men in our study and the study of Zhang et al., it seems that in our study, the higher BMI may have an effect on FABP-4 results, which requires further studies.

Our results also showed that serum FABP-4 level was higher in patients with AECOPD than in healthy subjects as well as SCOPD patients. In fact, these results indicate that FABP-4 may play a critical role in the development of COPD. Previous studies have reported that FABP-4 worsens inflammatory responses in inflammatory diseases by increasing levels of inflammatory cytokines or by recruiting inflammatory cells [24]. Perhaps FABP-4 plays a key role in the pathogenesis of COPD in the activation of transcription factors and release of inflammatory factors in macrophages. Since smoking has been shown to induce and activate macrophages, due to the strong correlation between FABP-4 and smoking in our study, at least in part, it can reflect the role of macrophages and their relationship with FABP-4 in pathogenesis of disease, especially in AECOPD condition. Animal studies have revealed that FABP-4-deficient macrophages have reduced inflammatory function and decreased inflammatory cytokines, such as IL-6, TNF-α, and MCP-1 [monocyte chemoattractant protein 1] [25]. In fact, mechanically, pharmacological or genetic inhibitors of FABP-4 had protective effects against inflammation through diminished chemokine and cytokine secretion, polarization of cells towards anti-inflammatory M2 condition, and production suppression of pro-inflammatory factors in hepatic tissue [11, 26, 27]. In addition, our
study results showed that there was a strong correlation between FABP-4 and IL-6 levels in patients with COPD, suggesting that adipokines such as FABP-4 may play a critical role in systemic inflammation of COPD patients. Particularly, the results revealed that serum levels of FABP-4 and IL-6 in the AECOPD patients were much higher than those in SCOPD patients. On the other hand, serum levels of FABP-4 in patients with AECOPD based on the severity of the disease in stages III-IV were greater than stages I-II, indicating that FABP-4 plays a major role in the development and persistence of inflammation in patients with COPD. Accordingly, increased levels of FABP-4 in patients with COPD can be indicative of local or systemic inflammation. Although adipose tissue and inflammatory cells such as macrophage are the main secretor source of FABP-4, it has also been shown that levels of FABP-4 are high in acute lung injury [28]. Of course, it should be noted that the authors did not rule out other pathways other than the inflammatory pathway of FABP-4 in patients with COPD. In patients with rheumatoid arthritis, it has been shown that increased levels of FABP-4 were associated with lipid profiles, independent of the severity of the disease, which indicates the predominant role of FABP-4 in lipid metabolism rather than inflammation pathway [14]. A significant negative correlation between SpO₂ and FABP-4 levels in our study may reveal another pathophysiological role of FABP-4 in COPD patients. In patients with COPD, one of the pathways activated as a result of hypoxia is endoplasmic reticulum stress response (ER stress). It has been shown that diminished FABP-4 can reduce the apoptosis mediated by ER stress [29]. Therefore, elevated FABP-4 level in patients with COPD, especially in the AECOPD phase may have an effect on ER stress markers and may affect oxygenation changes, which required further studies.
In this study, we additionally found a positive association between serum FABP-4 levels and CAT score plus mMRC scales. It has been reported that physical activity significantly decreases in patients with higher stages of COPD [30]. Another study also proposed that the increase in levels of inflammatory factors such as C-reactive protein, IL-6, and fibrinogen is the main cause for this diminished activity [31]. The rise in serum FABP-4 and IL-6 levels with increasing GOLD grades of COPD could correlate with the effect of systemic inflammation on health status.

Our study had some limitations. Since previous studies have shown that there was a gender difference in FABP-4 levels, we did not measure serum FABP-4 levels in female patients with COPD in the acute exacerbation phase. Further, we did not measure other inflammatory markers other than IL-6. Therefore, we are not able to determine the correlation between serum levels of FABP-4 and other inflammatory markers of COPD. Finally, the sample size of our study was small, and as such evaluations should be performed with a large sample size.

5. **Conclusion**

In this study, we found that serum FABP-4 and IL-6 levels increases with the enhanced GOLD grades in patients with COPD, markedly in acute exacerbation phase. The increase of FABP-4 had a strong relationship with elevated serum level of IL-6 and severity of hypoxia. Thus, serum FABP-4 levels merits consideration as a useful marker in the pathogenesis of COPD patients.

**References**

   doi: 10.1164/rccm.201701-0218PP.
3. Wouters EF, Groenewegen KH, Dentener MA, Vernooij JH. Systemic inflammation in
   chronic obstructive pulmonary disease: the role of exacerbations. Proceedings of the
4. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and
   upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary
   disease. American Journal of Respiratory and Critical Care Medicine 2006; 173 (1): 71-
   78. doi: 10.1164/rccm.200505-704OC.
5. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic
6. Fantuzzi G. Adipose tissue, adipokines, and inflammation. Journal of Allergy and
7. Aslani MR, Keyhanmanesh R, Khamaneh AM, Ebrahimi Saadatlou MA, Mesgari
   Abbasi M et al. Lung Altered Expression of IL-1beta mRNA and Its Signaling Pathway
   Molecules in Obese-asthmatic Male Wistar Rats. Iranian Journal of Allergy, Asthma, and
   overexpression of IL-1beta, IRAK-1 and TRAF-6 mRNA in obese-asthmatic male Wistar


16. Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty acid-binding protein 4 [FABP4]: pathophysiological insights and potent clinical biomarker of metabolic and...


22. Keyhanmanesh R, Alipour MR, Ebrahimi H, Aslani MR. Effects of Diet-Induced Obesity on Tracheal Responsiveness to Methacholine, Tracheal Visfatin Level, and Lung...


Table 1: Baseline characteristics of patients with COPD and control subjects

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control group</th>
<th>COPD group</th>
<th>AECOPD group</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (year)</td>
<td>58.13±7.36</td>
<td>57.97±9.27</td>
<td>59.43±6.59</td>
<td>0.730</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>26.29±3.52</td>
<td>26.27±4.83</td>
<td>24.47±4.38</td>
<td>0.174</td>
</tr>
<tr>
<td>Pulmonary function test:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 (% of predicted)</td>
<td>90.33±7.98</td>
<td>53.56±23.20</td>
<td>34.04±14.01</td>
<td>0.000</td>
</tr>
<tr>
<td>FVC (% of predicted)</td>
<td>85.40±9.26</td>
<td>68.20±22.26</td>
<td>49.53±21.72</td>
<td>0.000</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>86.70±4.21</td>
<td>58.76±9.77</td>
<td>55.08±11.24</td>
<td>0.000</td>
</tr>
<tr>
<td>FABP-4 (ng/mL)</td>
<td>0.80 (0.70-0.90)</td>
<td>0.90 (0.80-1.20)</td>
<td>1.10 (1-1.40)</td>
<td>0.000</td>
</tr>
<tr>
<td>IL-6 (ng/mL)</td>
<td>53.50 (43-58)</td>
<td>56 (53-61)</td>
<td>90.50 (76-109)</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD or median (25th–75th percentiles). AECOPD: acute exacerbation of COPD, SCOPD: stable COPD, FEV1: forced expiratory volume in 1 second, FVC: forced volume capacity, FABP-4: fatty acid binding protein 4, IL-6: interleukin 6.
### Table 2: GOLD groups and baseline characteristics of the study population

<table>
<thead>
<tr>
<th>Variables</th>
<th>GOLD I-II (SCOPD)</th>
<th>GOLD II (AECOPD)</th>
<th>GOLD III (SCOPD)</th>
<th>GOLD IV (AECOPD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Age (year)</td>
<td>BMI (kg/m²)</td>
<td>Smoking (pack per year)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>57.21±9.20</td>
<td>25.46±4.06</td>
<td>22 (20-28)</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>60.50±11.60</td>
<td>24.47±4.21</td>
<td>30 (15-58)</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>58.62±9.59</td>
<td>26.98±5.44</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>59.05±3.82</td>
<td>24.48±4.53</td>
<td>32.5 (27-39)</td>
</tr>
</tbody>
</table>

P<0.01

P<0.05

P<0.001

NS
<table>
<thead>
<tr>
<th></th>
<th>P1</th>
<th></th>
<th>P&lt;0.01</th>
<th></th>
<th>P&lt;0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are depicted as mean±SD or median (25th to 75th percentiles). 
### Table 3: Spearman correlation analysis of study parameters with FABP-4 in COPD patients (n=60)

<table>
<thead>
<tr>
<th>Variables</th>
<th>FABP-4</th>
<th>R</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td>0.069</td>
<td>0.599</td>
</tr>
<tr>
<td>Smoking history (per year)</td>
<td></td>
<td>0.608</td>
<td>0.000</td>
</tr>
<tr>
<td>FEV1 (% predicted)</td>
<td></td>
<td>-0.672</td>
<td>0.000</td>
</tr>
<tr>
<td>FVC (% predicted)</td>
<td></td>
<td>-0.651</td>
<td>0.000</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td></td>
<td>-0.242</td>
<td>0.060</td>
</tr>
<tr>
<td>GOLD grade</td>
<td></td>
<td>0.603</td>
<td>0.000</td>
</tr>
<tr>
<td>SpO2</td>
<td></td>
<td>-0.537</td>
<td>0.000</td>
</tr>
<tr>
<td>CAT score</td>
<td></td>
<td>0.693</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Table 4. Associations between FABP-4 and study parameters

<table>
<thead>
<tr>
<th>Variables</th>
<th>B</th>
<th>95% CI for B</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spo2</td>
<td>-0.059</td>
<td>-0.013 – 0.007</td>
<td>0.538</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.420</td>
<td>0.001 – 0.002</td>
<td>0.001</td>
</tr>
<tr>
<td>CAT score</td>
<td>0.361</td>
<td>0.007 – 0.021</td>
<td>0.000</td>
</tr>
<tr>
<td>Cigarette smoking</td>
<td>0.172</td>
<td>-0.000-0.006</td>
<td>0.093</td>
</tr>
</tbody>
</table>

B represents the unstandardized coefficient. CI: confidence intervals, FABP-4: fatty acid binding protein 4, IL-6: interleukin-6, SpO2: O2 saturation.
Figure 1: Individual values and median (25th to 75th percentiles) of serum levels of (a): FABP-4 and (b): IL-6 in study groups. For statistical differences between control group and other groups: *, $P < 0.05$; ***, $P < 0.001$. For statistical differences between stable COPD with acute exacerbation of COPD: **++; $P < 0.001$. FABP-4: fatty acid binding protein 4, IL-6: interleukin-6.
Figure 2: Serum levels of (a): FABP-4 and (b): IL-6 based on GOLD grade in stable and acute exacerbation of COPD patients. Data are depicted as median and quartiles range. GOLD: the Global Initiative for Chronic Obstructive Lung Disease, SCOPD: stable of chronic obstructive pulmonary disease, AECOPD: acute exacerbation of chronic obstructive pulmonary disease, FABP-4: fatty acid binding protein 4, IL-6: interleukin-6.
Figure 3: Spearman rank order correlation analysis of (a): FEV1 and FABP-4 serum levels (correlation coefficient = -0.716, $P=0.000$), (b): smoking history and FABP-4
serum levels (correlation coefficient = 0.619, $P=0.000$), (c): O$_2$ saturation and FABP-4
serum levels (correlation coefficient = -0.537, $P=0.000$), (d): FEV1 and IL-6 serum levels
(correlation coefficient = -0.666, $P=0.000$), (e): smoking history and IL-6 serum levels
(correlation coefficient = 0.644, $P=0.000$), (f): O$_2$ saturation and IL-6 serum levels
(correlation coefficient = -0.640, $P=0.000$), and (g): serum levels of FABP-4 and IL-6
(correlation coefficient = 0.692, $P=0.000$). FEV1: forced expiratory volume in 1 sec,
FABP-4: fatty acid binding protein 4, IL-6: interleukin-6, SpO$_2$: O$_2$-saturation.